Fracture risk assessment by the FRAX model

Abstract The introduction of the FRAX algorithms has facilitated the assessment of fracture risk on the basis of fracture probability. FRAX integrates the influence of several well-validated risk factors for fracture with or without the use of bone mineral density. Since age-specific rates of fracture and death differ across the world, FRAX models are calibrated with regard to the epidemiology of hip fracture (preferably from national sources) and mortality (usually United Nations sources). Models are currently available for 73 nations or territories covering more than 80% of the world population. FRAX has been incorporated into more than 80 guidelines worldwide, although the nature of this application has been heterogeneous. The limitations of FRAX have been extensively reviewed. Arithmetic procedures have been proposed in order to address some of these limitations, which can be applied to conventional FRAX estimates to accommodate knowledge of dose exposure to glucocorticoids, concurrent data on lumbar spine bone mineral density, information on trabecular bone score, hip axis length, falls history, type 2 diabetes, immigration status and recency of prior fracture.

[1]  J. Kanis,et al.  An assessment of intervention thresholds for very high fracture risk applied to the NOGG guidelines , 2021, Osteoporosis International.

[2]  J. Kanis,et al.  Romosozumab efficacy on fracture outcomes is greater in patients at high baseline fracture risk: a post hoc analysis of the first year of the frame study , 2021, Osteoporosis International.

[3]  J. Kanis,et al.  Global impact of COVID-19 on non-communicable disease management: descriptive analysis of access to FRAX fracture risk online tool for prevention of osteoporotic fractures , 2020, Osteoporosis International.

[4]  J. Kanis,et al.  Adjusting conventional FRAX estimates of fracture probability according to the recency of sentinel fractures , 2020, Osteoporosis International.

[5]  P. Geusens,et al.  Efficacy of teriparatide compared with risedronate on FRAX®-defined major osteoporotic fractures: results of the VERO clinical trial , 2020, Osteoporosis International.

[6]  T. Peters,et al.  Long-term cost-effectiveness of screening for fracture risk in a UK primary care setting: the SCOOP study , 2020, Osteoporosis International.

[7]  Jennifer E. Moore,et al.  Agency for Healthcare Research and Quality , 2020, Definitions.

[8]  J. Kanis,et al.  A decade of FRAX: how has it changed the management of osteoporosis? , 2020, Aging Clinical and Experimental Research.

[9]  H. E. van der Horst,et al.  Fracture prevention by screening for high fracture risk: a systematic review and meta-analysis , 2019, Osteoporosis International.

[10]  C. Cooper,et al.  Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures , 2019, Osteoporosis International.

[11]  F. Rutters,et al.  The Effect of a Screening and Treatment Program for the Prevention of Fractures in Older Women: A Randomized Pragmatic Trial , 2019, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[12]  J. Kanis,et al.  Temporal changes in access to FRAX® in Thailand between 2010 and 2018 , 2019, Archives of Osteoporosis.

[13]  J. Kanis,et al.  Effect of abaloparatide on vertebral, nonvertebral, major osteoporotic, and clinical fractures in a subset of postmenopausal women at increased risk of fracture by FRAX probability , 2019, Archives of Osteoporosis.

[14]  J. Kanis,et al.  A brief history of FRAX , 2018, Archives of Osteoporosis.

[15]  J. Kanis,et al.  Comparison of Methods for Improving Fracture Risk Assessment in Diabetes: The Manitoba BMD Registry , 2018, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[16]  M. Phipps,et al.  Screening for Osteoporosis to Prevent Fractures: US Preventive Services Task Force Recommendation Statement , 2018, JAMA.

[17]  P. Geusens,et al.  Effects of Teriparatide Compared with Risedronate on the Risk of Fractures in Subgroups of Postmenopausal Women with Severe Osteoporosis: The VERO Trial , 2018, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[18]  C. Cooper,et al.  The Cost‐Effectiveness of Screening in the Community to Reduce Osteoporotic Fractures in Older Women in the UK: Economic Evaluation of the SCOOP Study , 2018, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[19]  C. Cooper,et al.  Screening in the community to reduce fractures in older women (SCOOP): a randomised controlled trial , 2017, The Lancet.

[20]  P. Geusens,et al.  Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial , 2017, The Lancet.

[21]  M. Leshno,et al.  Fracture Risk Assessment With FRAX Using Real-World Data in a Population-Based Cohort From Israel , 2018, American journal of epidemiology.

[22]  J. Kanis,et al.  FRAX-based intervention and assessment thresholds in seven Latin American countries , 2018, Osteoporosis International.

[23]  M. Bech,et al.  Effectiveness of a two-step population-based osteoporosis screening program using FRAX: the randomized Risk-stratified Osteoporosis Strategy Evaluation (ROSE) study , 2018, Osteoporosis International.

[24]  A. Grauer,et al.  Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis , 2017, The New England journal of medicine.

[25]  J. Kanis,et al.  The Effect of Abaloparatide‐SC on Fracture Risk Is Independent of Baseline FRAX Fracture Probability: A Post Hoc Analysis of the ACTIVE Study , 2017, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[26]  E. Skovlund,et al.  Validation of FRAX and the impact of self-reported falls among elderly in a general population: the HUNT study, Norway , 2017, Osteoporosis International.

[27]  Ran D Balicer,et al.  External validation and comparison of three prediction tools for risk of osteoporotic fractures using data from population based electronic health records: retrospective cohort study , 2017, British Medical Journal.

[28]  J. Kanis,et al.  FRAX Update. , 2017, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

[29]  C. Cooper,et al.  A systematic review of intervention thresholds based on FRAX , 2016, Archives of Osteoporosis.

[30]  J. Kanis,et al.  Adjusting Hip Fracture Probability in Men and Women Using Hip Axis Length: the Manitoba Bone Density Database. , 2016, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

[31]  Jacques P. Brown,et al.  A Meta‐Analysis of Trabecular Bone Score in Fracture Risk Prediction and Its Relationship to FRAX , 2016, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[32]  J. Kanis,et al.  Intervention Thresholds and the Diagnosis of Osteoporosis , 2015, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[33]  J. Kanis,et al.  FRAX and the effect of teriparatide on vertebral and non-vertebral fracture , 2015, Osteoporosis International.

[34]  J. Kanis,et al.  Efficacy of weekly teriparatide does not vary by baseline fracture probability calculated using FRAX , 2015, Osteoporosis International.

[35]  C. Cooper,et al.  FRAX-based assessment and intervention thresholds—an exploration of thresholds in women aged 50 years and older in the UK , 2015, Osteoporosis International.

[36]  D. Mellström,et al.  Is the Swedish FRAX model appropriate for Swedish immigrants? , 2015, Osteoporosis International.

[37]  J. Kanis,et al.  Adjusting Fracture Probability by Trabecular Bone Score , 2015, Calcified Tissue International.

[38]  A. LaCroix,et al.  Impact of Femoral Neck and Lumbar Spine BMD Discordances on FRAX Probabilities in Women: A Meta-analysis of International Cohorts , 2014, Calcified Tissue International.

[39]  J. Cauley,et al.  Geographic and ethnic disparities in osteoporotic fractures , 2014, Nature Reviews Endocrinology.

[40]  C. Cooper,et al.  Worldwide uptake of FRAX , 2014, Archives of Osteoporosis.

[41]  E. M. Lewiecki,et al.  Clinician’s Guide to Prevention and Treatment of Osteoporosis , 2014, Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA.

[42]  Naoto Endo,et al.  Japanese 2011 guidelines for prevention and treatment of osteoporosis—executive summary , 2012, Archives of Osteoporosis.

[43]  S. Cummings,et al.  Effect of alendronate for reducing fracture by FRAX score and femoral neck bone mineral density: The fracture intervention trial , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[44]  J. Kanis,et al.  Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[45]  J. Kanis,et al.  Does osteoporosis therapy invalidate FRAX for fracture prediction? , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[46]  Carol Coupland,et al.  Derivation and validation of updated QFracture algorithm to predict risk of osteoporotic fracture in primary care in the United Kingdom: prospective open cohort study , 2012, BMJ : British Medical Journal.

[47]  C. Cooper,et al.  A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis , 2012, Osteoporosis International.

[48]  C. Cooper,et al.  A systematic review of hip fracture incidence and probability of fracture worldwide , 2012, Osteoporosis International.

[49]  C. Cooper,et al.  European guidance for the diagnosis and management of osteoporosis in postmenopausal women , 2008, Osteoporosis International.

[50]  S. Boonen,et al.  Official Positions for FRAX® clinical regarding falls and frailty: can falls and frailty be used in FRAX®? From Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®. , 2011, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

[51]  J. Kanis,et al.  FRAX® with and without Bone Mineral Density , 2011, Calcified Tissue International.

[52]  L. Lix,et al.  Fracture risk assessment without bone density measurement in routine clinical practice , 2011, Osteoporosis International.

[53]  W. Leslie,et al.  Fracture prediction and calibration of a Canadian FRAX® tool: a population-based report from CaMos , 2011, Osteoporosis International.

[54]  J. Kanis,et al.  Spine–hip discordance and fracture risk assessment: a physician-friendly FRAX enhancement , 2011, Osteoporosis International.

[55]  J. Kanis,et al.  Guidance for the adjustment of FRAX according to the dose of glucocorticoids , 2011, Osteoporosis International.

[56]  Eugene McCloskey,et al.  Independent clinical validation of a Canadian FRAX tool: Fracture prediction and model calibration , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[57]  J. Kanis,et al.  A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX. , 2010, Bone.

[58]  R. Chou,et al.  Screening for Osteoporosis , 2010 .

[59]  Carol Coupland,et al.  Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores , 2009, BMJ : British Medical Journal.

[60]  J. Kanis,et al.  Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. , 2009, Bone.

[61]  C. Cooper,et al.  Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. , 2009, Maturitas.

[62]  J. Kanis,et al.  Ten-year fracture probability identifies women who will benefit from clodronate therapy—additional results from a double-blind, placebo-controlled randomised study , 2009, Osteoporosis International.

[63]  C. Cooper,et al.  European guidance for the diagnosis and management of osteoporosis in postmenopausal women , 2008, Osteoporosis International.

[64]  L. Melton,et al.  A reference standard for the description of osteoporosis. , 2008, Bone.

[65]  L. Melton,et al.  Cost-effective osteoporosis treatment thresholds: the United States perspective , 2008, Osteoporosis International.

[66]  O. Johnell,et al.  FRAX™ and the assessment of fracture probability in men and women from the UK , 2008, Osteoporosis International.

[67]  G. Anderson,et al.  Predicting risk of breast cancer in postmenopausal women by hormone receptor status. , 2007, Journal of the National Cancer Institute.

[68]  N. D. Nguyen,et al.  Development of a nomogram for individualizing hip fracture risk in men and women , 2007, Osteoporosis International.

[69]  Jacques P. Brown,et al.  The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women , 2007, Osteoporosis International.

[70]  COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE ( CHMP ) GUIDELINE ON CONDUCT OF PHARMACOVIGILANCE FOR MEDICINES USED BY THE PAEDIATRIC POPULATION , 2007 .

[71]  O. Johnell,et al.  Requirements for DXA for the management of osteoporosis in Europe , 2005, Osteoporosis International.

[72]  O. Johnell,et al.  Optimization of BMD Measurements to Identify High Risk Groups for Treatment—A Test Analysis , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.